Alaunos Therapeutics, Inc.
TCRTNASDAQHealthcare● Active
$2.00
$-0.28(-12.28%)
Market Cap$4884292
P/E Ratio—
52W High$6.2
52W Low$1.67
Alaunos Therapeutics, Inc. (TCRT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TCRT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.01M | $0.01M | $0.01M | $2.92M | $0.40M |
| Cost of Revenue | $0.00M | $0.00M | $4.80M | $0.00M | $0.00M |
| Gross Profit | $0.01M | $0.01M | ($4.80M) | $2.92M | $0.40M |
| Gross Margin %(computed) | 100.00% | 100.00% | — | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $1.36M | $0.36M | $16.28M | $25.02M | $49.64M |
| G&A Expenses | $2.87M | $4.46M | $12.22M | $13.14M | $27.56M |
| Total Operating Expenses | $4.23M | $4.82M | $29.47M | $38.03M | $77.95M |
| Operating Income | ($4.22M) | ($4.81M) | ($34.27M) | ($35.10M) | ($77.55M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $1.92M | $3.15M | $1.19M |
| Income Before Tax | ($4.18M) | ($4.68M) | ($35.14M) | ($37.73M) | ($78.75M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($4.18M) | ($4.68M) | ($35.14M) | ($37.73M) | ($78.75M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.20 | $-2.92 | $-21.97 | $-25.97 | $-53.80 |
| Wtd Avg Shares | 1.95M | 1.60M | 1.60M | 1.45M | 1.43M |
| EBITDA | ($4.22M) | ($4.68M) | ($30.90M) | ($31.82M) | ($74.97M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Alaunos Therapeutics, Inc. data
About Alaunos Therapeutics, Inc. (TCRT) Income Statement
Alaunos Therapeutics, Inc. (TCRT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TCRT reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.00B) — a net profit margin of -83520.00%.
Frequently asked questions
TCRT · 4 questionsAlaunos Therapeutics, Inc. (TCRT) reported revenue of $0.00B for 2025, down 50.0% year-over-year.
TCRT revenueTCRT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08